论文部分内容阅读
目的观察经持续皮下注射胰岛素强化治疗的2型糖尿病患者改用甘精胰岛素加瑞格列奈治疗的有效性、安全性及患者依从性。方法将46例经持续皮下注射胰岛素强化治疗达标的2型糖尿病患者随机分为每日1次甘精胰岛素加三餐前口服瑞格列奈组和每日2次混合精蛋白锌重组人胰岛素组。8周后比较两组糖化血红蛋白、三餐前、三餐后及睡前血糖,患者依从性和满意率通过问卷调查来统计。结果两组间糖化血红蛋白无显著性差异;甘精胰岛素组中餐前、后血糖均低于精蛋白锌重组人胰岛素组,且两组低血糖发生率相似,无显著性差异;甘精胰岛素组患者的依从性和满意率明显高于精蛋白锌重组人胰岛素组。结论胰岛素强化治疗后的2型糖尿病患者改用甘精胰岛素加瑞格列奈治疗有较好的疗效和安全性,患者依从性好、满意率高。
Objective To investigate the efficacy, safety and compliance of patients switched to insulin glargine and repaglinide for type 2 diabetes mellitus with continuous subcutaneous insulin injections. Methods A total of 46 patients with type 2 diabetes mellitus undergoing continuous subcutaneous injection of insulin-intensive therapy were randomly assigned to receive glargine plus oral repaglinide three times daily and methotrexate recombinant human insulin twice daily . After 8 weeks, two groups of glycosylated hemoglobin, three meals before, three meals and before going to bed blood glucose were compared. Patient compliance and satisfaction rate were calculated by questionnaire. Results There was no significant difference between the two groups in glycosylated hemoglobin; before and after the glargine group, the blood glucose level was lower than that of the protamine zinc group, and the incidence of hypoglycemia was similar between the two groups. There was no significant difference between the glargine group The compliance and satisfaction rates were significantly higher than those of the protamine zinc recombinant human insulin group. Conclusion Intensive insulin therapy in patients with type 2 diabetes instead of glargine and repaglinide treatment has better efficacy and safety, patient compliance is good, the satisfaction rate is high.